
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is a clinical-stage biopharmaceutical company with a positive outlook due to its potential in addressing the unmet need for new treatments in pediatric and young adult osteosarcoma. Its pipeline of product candidates targeting multiple indications for solid cancers, including the lead drug OST-HER2, has promising clinical data and notable regulatory designations. With potential global regulatory alignment, a strong clinical development plan, and potential market entry in 2026, the company presents as an attractive investment opportunity.
Bears say
OS Therapies is a clinical-stage biopharmaceutical company with a focus on developing treatments for Osteosarcoma (OS) and other solid tumors. While the company has promising pipeline candidates and has received regulatory validation with the initiation of a rolling review for OST-HER2 in Europe, its heavy cost structure and need for continued financing raise concerns about its ability to execute on upcoming milestones. Ultimately, the company's success will depend on its ability to translate positive Phase 2b and biomarker data into a viable accelerated approval path.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares